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September 4, 2012:947–9blocker (ARB) use (92%), whereas the frequency of ACEI/ARB use
was significantly less in the advanced decompensated heart failure
group (61%) (p 0.0001). This difference might affect interpretation
of the ADMA findings, because ACEI/ARBs decrease circulating
ADMA levels (2). Moreover, these medications may affect DDAH
expression and/or activity (3). Shao et al. also reported higher
DDAH-1 expression in hearts from patients who had heart failure
but did not have elevated systolic pulmonary artery pressure compared
with controls and heart failure patients who did have elevated systolic
pulmonary artery pressure, suggesting a successful compensatory effect of
DDAH-1 up-regulation. It may be interesting to evaluate ACEI/ARB
treatment differences among these groups.
In addition, the authors (1) note the importance of both ADMA
production and elimination in controlling ADMA and conclude, on
the basis of DDAH and protein arginine methyltransferase expression
patterns, that reduced elimination is likely responsible for the observed
elevated ADMA levels. Although this hypothesis may ultimately be
true, it is worth noting that proteolysis is necessary for ADMA release
and, hence, accumulation. It has been noted that high concentrations
of protein-incorporated ADMA are present in, and proteolytically
released from, erythrocytes (4). Because high protein turnover may yield
reater ADMA release and because heart failure is associated with
achexia, it might be reasonable to consider protein turnover when
valuating ADMA dysregulation in congestive heart failure.
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Reply
We thank Dr. Billecke and colleagues for their interest in our
paper (1) and agree that various treatments may directly or
indirectly affect asymmetric dimethylarginine levels, and based on
our findings we postulated that modulating dimethylarginine
dimethylaminohydrolase-1 activity with pharmacotherapy can be a
potential therapeutic approach. Nevertheless when comparing be-
tween those with chronic versus advanced decompensated heart
failure who were on angiotensin-converting enzyme inhibitors, levels
of methylated arginine metabolites and arginine bioavailability re-
mained significantly different. This suggested that the underlying
disease severity remains an important determinant. Whether proteol-
ysis and protein turnover can contribute to in vivo asymmetric
dimethylarginine release, particularly during catabolic or hemolytic
processes associated with pulmonary venous hypertension in advanced
heart failure, may warrant further investigation.
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